{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:13:02Z","timestamp":1778933582158,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":889,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.exphem.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T10:54:15Z","timestamp":1579085655000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells"],"prefix":"10.1016","volume":"81","author":[{"given":"Benigno C.","family":"Valdez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6453","authenticated-orcid":false,"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.01.003_bib0001","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2007","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exphem.2020.01.003_bib0002","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1705580","article-title":"Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma","volume":"39","author":"Qazilbash","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.01.003_bib0003","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in longterm survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.01.003_bib0004","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2010.02.015","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma","volume":"16","author":"Efebera","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0006","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.22273","article-title":"Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"87","author":"Bashir","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0007","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2352-3026(17)30080-7","article-title":"High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan","volume":"4","author":"Nieto","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0008","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/107327481101800406","article-title":"Advances in the autologous and allogeneic transplantation strategies for multiple myeloma","volume":"18","author":"Nishihori","year":"2011","journal-title":"Cancer Control"},{"key":"10.1016\/j.exphem.2020.01.003_bib0009","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.exphem.2020.01.003_bib0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/14737140.2015.1047770","article-title":"Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"15","author":"Richardson","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.exphem.2020.01.003_bib0011","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2020.01.003_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2020.01.003_bib0013","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17474086.2017.1366852","article-title":"Targeted therapies in acute myeloid leukemia: a focus on FLT-3 inhibitors and ABT199","volume":"10","author":"Naqvi","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0014","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2020.01.003_bib0015","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.01.003_bib0016","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.clml.2018.06.003","article-title":"Venetoclax in combination with bortezomib, dexamethasone, and daratumumab for multiple myeloma","volume":"18","author":"Rahbari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2020.01.003_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2020.01.003_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.exphem.2020.01.003_bib0019","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbmt.2012.05.011","article-title":"High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies","volume":"18","author":"Nieto","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.01.003_bib0020","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bbmt.2018.02.020","article-title":"Phase II trial of high-dose gemcitabine\/busulfan\/melphalan with autologous stem cell transplantation for primary refractory or poor-risk relapsed Hodgkin lymphoma","volume":"24","author":"Nieto","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.01.003_bib0021","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.exphem.2012.06.001","article-title":"Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analogue-DNA alkylating agents in lymphoma cell lines","volume":"40","author":"Valdez","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0022","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3109\/10428194.2016.1157871","article-title":"Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells","volume":"57","author":"Teo","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2020.01.003_bib0023","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10428194.2017.1306647","article-title":"The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells","volume":"58","author":"Valdez","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2020.01.003_bib0024","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30100","article-title":"Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma","volume":"122","author":"Nieto","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2020.01.003_bib0025","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.bbmt.2015.06.003","article-title":"Vorinostat combined with high-dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas","volume":"21","author":"Nieto","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2020.01.003_bib0026","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2020.01.003_bib0027","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.01.003_bib0028","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2020.01.003_bib0029","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/biom5042877","article-title":"ATM-dependent phosphorylation of all three members of the MRN complex: From sensor to adaptor","volume":"5","author":"Lavin","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.exphem.2020.01.003_bib0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2020.01.003_bib0031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/284555a0","article-title":"Glucocorticoid induced thymocyte apoptosis is associated with endogenous endonuclease activation","volume":"284","author":"Wyllie","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2020.01.003_bib0032","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000491908","article-title":"Metformin and FTY720 synergistically induce apoptosis in multiple myeloma cells","volume":"48","author":"Zhao","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.exphem.2020.01.003_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.exphem.2020.01.003_bib0034","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4149\/gpb_2017026","article-title":"ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells","volume":"37","author":"Choi","year":"2018","journal-title":"Gen Physiol Biophys"},{"key":"10.1016\/j.exphem.2020.01.003_bib0035","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1242\/jcs.01540","article-title":"The AMP-activated protein kinase pathway\u2014new players upstream and downstream","volume":"117","author":"Hardie","year":"2004","journal-title":"J Cell Sci"},{"key":"10.1016\/j.exphem.2020.01.003_bib0036","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-15-0068","article-title":"Dissecting the dual role of AMPK in cancer: From experimental to human studies","volume":"13","author":"Zadra","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2020.01.003_bib0037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2020.01.003_bib0038","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0014-5793(97)00323-2","article-title":"The modular phosphorylation and activation of p70s6k","volume":"410","author":"Pullen","year":"1997","journal-title":"FEBS Let"},{"key":"10.1016\/j.exphem.2020.01.003_bib0039","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1096\/fasebj.10.12.8903508","article-title":"The eIF-2alpha kinases and the control of protein synthesis","volume":"10","author":"de Haro","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2020.01.003_bib0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcell.2018.00013","article-title":"Subcellular localization and dynamics of the Bcl-2 family of proteins","volume":"6","author":"Popgeorgiev","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000415","article-title":"BiP binding to the ER-stress sensor Ire1 tunes the homeostatic behavior of the unfolded protein response","volume":"8","author":"Pincus","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0042","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1083\/jcb.200311055","article-title":"Oxidative protein folding in eukaryotes: mechanisms and consequences","volume":"164","author":"Tu","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0043","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.redox.2017.07.010","article-title":"Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells","volume":"13","author":"Park","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0044","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrm.2016.14","article-title":"Nuclear DNA damage signaling to mitochondria in ageing","volume":"17","author":"Fang","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2020.01.003_bib0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/em.20603","article-title":"Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies","volume":"51","author":"Valdez","year":"2010","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.exphem.2020.01.003_bib0046","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1748-1716.2009.01972.x","article-title":"LKB1 and AMP-activated protein kinase control of mTOR signalling and growth","volume":"196","author":"Shaw","year":"2009","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.exphem.2020.01.003_bib0047","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1535-7163.MCT-10-0777","article-title":"AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia","volume":"10","author":"Kuznetsov","year":"2011","journal-title":"Mol Cancer Ther"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20300035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20300035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:33:46Z","timestamp":1759566826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20300035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":47,"alternative-id":["S0301472X20300035"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.01.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}